Immune-Onc Therapeutics
Biotechnology ResearchCalifornia, United States11-50 Employees
Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a private, clinical-stage oncology company dedicated to discovering and developing novel biotherapeutics targeting myeloid cell inhibitory receptors. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. Immune-Onc has a differentiated pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB). Immune-Onc’s focused platform approach has led to the development of several promising therapeutics across various stages of development. Those include IO-108, an antagonist antibody targeting LILRB2 (also known as ILT4), in Phase 1b/2 clinical development for solid tumors, and IO-202, a first-in-class antagonist antibody targeting LILRB4 (also known as ILT3), in Phase 1b clinical development for the treatment of acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors. Additional assets in Immune-Onc’s pipeline include IO-106 (first-in-class antagonist antibody targeting LAIR1), IO-312 (a novel bispecific antibody targeting LILRB4 and CD3), and undisclosed immunology and oncology programs. For more information, please visit www.immune-onc.com.
1-888-653-2347 
support@leadiq.com 
